NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Plan to boost special education nationally
- Harnessing AI to narrow world tech gap
- Embrace of cultures still best lesson on understanding
- Top court sets rules to curb AI misuse
- Hulunbuir launches autumn peak season as forests turn gold and crimson
- Parents urged to build healthier habits as new semester begins
